COMPASS Pathways plc (CMPS)
COMPASS Pathways is a UK biotechnology company developing COMP360, a psilocybin-based treatment for serious mental health conditions. It last closed at $7.98 on Nov 17, down 3.51% on the day. The average 12-month price target from 2 analysts is $37.50 (+369.9% from the last close), with a high of $65.00 and a low of $10.00.
Key Stats
Last 12 monthsNot reported for this period.
From CMPS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on CMPS in the past 90 days. The average target is $37.50, with a high of $65.00 and a low of $10.00, compared with the last close of $7.98.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | HC Wainwright & Co. | Reiterated | Buy | $65 |
| Nov 4 | Wells Fargo | Target lowered | Hold | $13 → $10 |
| Aug 7 | HC Wainwright & Co. | Maintained | Buy | $65 |
| Aug 6 | B. Riley Securities | Target raised | Buy | $17 → $22 |
| Jul 27 | Wells Fargo | Initiated | Hold | $13 |
Technical Analysis
The stock is 24% below its 20 day and 46% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $7.72, and the nearest resistance the Pivot at $8.07.
| RSI (14) | 32.33 | Weak, oversold below 30 | Neutral |
| MACD | -0.93 | Below its signal line | Bearish |
| Stochastic | 17.7 | Near the bottom of its range | Oversold |
| ADX (14) | 34.9 | Trending down | |
| Williams %R | -91.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -88.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −7.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.79 | Typical daily range, 9.9% of price |
| RSI (14) | 37.26 | Weak, oversold below 30 | Neutral |
| MACD | -0.30 | Below its signal line | Bearish |
| Stochastic | 11.9 | Near the bottom of its range | Oversold |
| ADX (14) | 33.1 | Trending down | |
| Williams %R | -94.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -181.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −44.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.78 | Typical daily range, 22.3% of price |
What happened before
See how CMPS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CMPS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in CMPS in the last 90 days.
CMPS Institutional Ownership
Full report →- ▲127 buying vs 96 selling
- ▲Held by funds +5.9 pts
- ▲Funds holding +12
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 237 | 225 | +5.3% |
| In funds' top 10 | 9 | 10 | −10.0% |
| Held by funds | 70.6% | 64.7% | +5.9 pts |
| New / increased | 50 / 77 | 60 / 74 | −5.2% |
| Reduced / sold out | 56 / 40 | 48 / 30 | +23.1% |
| Put/call ratio | 0.13 | 0.10 | +25.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPS is in one of them and how their past CMPS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CMPS in an article yet. Here's the latest on the wider market.
About COMPASS Pathways
COMPASS Pathways is a biotechnology company based in the United Kingdom. It is developing COMP360, a treatment built around psilocybin for serious mental health conditions, with its current focus on depression that has not responded to standard medicines. The company is also running a clinical trial for PTSD. If approved, it plans to offer the treatment to patients through healthcare providers in the U.S.
- Headquarters
- Chesire, United Kingdom
- Founded
- 2016
- Website
- compasspathways.com ↗




